Abstract
Sodium borocaptate (BSH) is widely used for boron neutron capture therapy (BNCT) of brain tumors. One drawback is the large uptake by the liver causing a decrease of its availability at the tumor region as well as bringing about toxicity problems. A novel carborane-based compound containing a boron payload very similar to that of BSH has been synthesized and tested on rat glioma (C6) cells, hepatoma tissue culture (HTC) cells, and hepatocytes. The newly synthesized system consists of an o-carborane unit (C2B10H11, o-CB) conjugated to a glutamine residue through a proper spacer, namely, o-CB-Gln. As compared with BSH, it showed the same uptake by C6 cells, but a 50% decrease in uptake by HTC cells and an 80% decrease in uptake by healthy hepatocytes. On this basis o-CB-Gln appears an interesting candidate for BNCT of brain tumors as it is expected to have a therapeutic index analogous to that of BSH accompanied by a much lower liver toxicity.
Graphical Abstract
A novel carborane based compound, consisting in an o-carborane unit (C2B10H11, o-CB) conjugated to a glutamine residue through a proper spacer (namely o-CB-Gln) has been synthesized, characterized and tested on rat glioma (C6), hepatoma (HTC) and hepatocytes. As compared to sodium borocaptate (BSH), widely used for boron neutron capture therapy (BNCT) of brain tumors, the newly synthesized system showed the same uptake by C6 cells, but a 50% decrease by HTC and 80% decrease by healthy hepatocytes. On this basis o-CB-Gln appears an interesting candidate for BNCT of brain tumors as it is expected to have a therapeutic index analogous to BSH accompanied by a much lower liver toxicity.
Similar content being viewed by others
References
Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG (1998) Chem Rev 98:1515–1562
Barth RF, Coderre JA, Vicente MGH, Blue TE (2005) Clin Cancer Res 11:3987–4002
Coderre JA, Turcotte JC, Riley KJ, Binns PJ, Harling OK, Kiger WS (2003) Technol Cancer Res Treat 2:355–375
Hawthorne FM, Lee MW (2003) J Neuro Oncol 62:33–45
Hawthorne FM (1993) Angew Chem Int Ed Engl 32:950–984
Hawthorne MF, Maderna A (1999) Chem Rev 99:3421–3434
Warburg O (1956) Science 123:309–314
Medina MA (2001) J Nutr 131:2539S–2542S
Medina MA, Sanchezjimenez F, Marquez J, Quesada AR, Decastro IN (1992) Mol Cell Biochem 113:1–15
Geninatti Crich S, Cabella C, Barge A, Belfiore S, Ghirelli C, Lattuada L, Lanzardo S, Mortillaro A, Tei L, Visigalli M, Forni G, Aime S (2006) J Med Chem 49:4926–4936
Fuchs BC, Perez JC, Suetterlin JE, Chaudhry SB, Bode BP (2004) Am J Physiol Gastroint Liver Physiol 286:G467–G478
Dolinska M, Dybel A, Zablocka B, Albrecht J (2003) Neurochem Int 43:501–507
Amarengo WLF, Perrin DD (1996) Purification of laboratory chemicals. Butterworth-Heinemann, Oxford
Labbe G, Leurs S, Sannen I, Dehaen W (1993) Tetrahedron 49:4439–4446
Kusari U, Li Y, Bradley MG, Sneddon LG (2004) J Am Chem Soc 126:8662–8663
Wilson AJC (1992) International tables for X-ray crystallography, vol C. Kluwer, Dordrecht
Sieber P, Riniker B (1991) Tetrahedron Lett 32:739–742
Xu J, Kullgren B, Durbin PW, Raymond KN (1995) J Med Chem 38:2606–2614
Gardini G, Cabella C, Cravanzola C, Vargiu C, Belliardo S, Testore G, Solinas SP, Toninello A, Grillo MA, Colombatto S (2001) J Hepatol 35:482–489
Haselberger K, Radner H, Gossler W, Schlagenhaufen C, Pendl G (1994) J Neurosurg 81:741–744
Yang WL, Barth RF, Rotaru JH, Moeschberger ML, Joel DD, Nawrocky MM, Goodman JH, Soloway AH (1997) Int J Radiat Oncol Biol Phys 37:663–672
Yoshida F, Matsumura A, Yamamoto T, Kumada H, Nakai K (2004) Cancer Lett 215:61–67
Yoshida F, Yamamoto T, Nakai K, Kumada H, Shibata Y, Tsuruta W, Endo K, Tsurubuchi T, Matsumura A (2008) Cancer Lett 263:253–258
Yong JH, Barth RF, Rotaru JH, Wyzlic IM, Soloway AH (1995) Anticancer Res 15:2039–2043
Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, Kumada H, Sakurai Y, Masunaga SI, Ono K, Miyatake SI (2008) J Neurooncol 87:287–294
Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA (2004) J Hepatol 40:212–218
Acknowledgments
The authors gratefully acknowledge Regione Piemonte (project no. A97/2004) and Compagnia San Paolo for financial support. This work was supported by MIUR (PRIN and FIRB projects), Meditrans IP, EMIL, and DiMI EU NoEs.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crivello, A., Nervi, C., Gobetto, R. et al. Towards improved boron neutron capture therapy agents: evaluation of in vitro cellular uptake of a glutamine-functionalized carborane. J Biol Inorg Chem 14, 883–890 (2009). https://doi.org/10.1007/s00775-009-0500-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-009-0500-1